Human CCR3 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB155
Clone 61828 was used by HLDA to establish CD designation
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
CyTOF-ready, Flow Cytometry, Immunohistochemistry, Neutralization
Cited:
Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG2A Clone # 61828
Product Specifications
Immunogen
Y3 rat myeloid cell line transfected with human CCR3
Accession # P51677
Accession # P51677
Specificity
Detects human CCR3 transfectants in flow cytometry. In flow cytometry, no cross-reactivity with CCR1, CCR2, CCR5, and CCR6 transfectants or the parental cell line is observed. Detects CCR3 on peripheral blood eosinophils.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2A
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CCR3 Antibody
CCR3 in Human Lymph Node.
CCR3 was detected in immersion fixed paraffin-embedded sections of human lymph node using 15 µg/mL Rat Anti-Human CCR3 Monoclonal Antibody (Catalog # MAB155) overnight at 4 °C. Tissue was stained with the Anti-Rat HRP-AEC Cell & Tissue Staining Kit (red; Catalog # CTS018) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.Chemotaxis Induced by CCL11/Eotaxin and Neutralization by Human CCR3 Antibody.
Recombinant Human CCL11/Eotaxin (Catalog # 320-EO) chemoattracts the BaF3 mouse proB cell line transfected with human CCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant CCL11/Eotaxin (0.333 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Human CCR3 Monoclonal Antibody (Catalog # MAB155). The ND50 is typically 0.05-0.25 µg/mL.Applications for Human CCR3 Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
2.5 µg/106 cells
Sample: Human CD49d+ peripheral blood cells
Sample: Human CD49d+ peripheral blood cells
Immunohistochemistry
8-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human lymph node
Sample: Immersion fixed paraffin-embedded sections of human lymph node
Neutralization
Measured by its ability to neutralize CCL11/Eotaxin-induced chemotaxis in the BaF3 mouse proB cell line transfected with human CCR3. The Neutralization Dose (ND50) is typically 0.05-0.25 µg/mL in the presence of 0.333 µg/mL Recombinant Human CCL11/Eotaxin.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 1 review rated 5 using MAB155 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCR3
Alternate Names
CCR3, CD193
Gene Symbol
CCR3
UniProt
Additional CCR3 Products
Product Documents for Human CCR3 Antibody
Product Specific Notices for Human CCR3 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...